Return On Equity
341%
Trailing 12 months · Through 30 Sep 2024
YoY relative change: -140%
Cyclo Therapeutics, Inc. financial metrics
Period Q3 2024 · Filed 18 Dec 2024
Key metrics snapshot
Return On Assets
-457%
Trailing 12 months · Through 30 Sep 2024
YoY relative change: +66%
Current Ratio
0.17x
Period-end balance · Through 30 Sep 2024
YoY relative change: -79%
Quick Ratio
0.06x
Period-end balance · Through 30 Sep 2024
YoY relative change: -81%
NetIncomeLoss YoY
-28%
Trailing 12 months · Through 30 Sep 2024
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
341%
Trailing 12 months · 30 Sep 2024
|
-140% |
| Return On Assets |
-457%
Trailing 12 months · 30 Sep 2024
|
+66% |
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.17x
Period-end balance · 30 Sep 2024
|
-79% |
| Quick Ratio |
0.06x
Period-end balance · 30 Sep 2024
|
-81% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-28%
Trailing 12 months · 30 Sep 2024
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
28,768,055
Period-end balance · 12 Nov 2024
|
+27% |
| Common Stock, Shares, Outstanding |
28,768,055
Period-end balance · 30 Sep 2024
|
+49% |
| Common Stock, Value, Issued |
$0
Period-end balance · 30 Sep 2024
|
-100% |
| Weighted Average Number of Shares Outstanding, Basic |
28,729,641
Reported period · 30 Sep 2024
|
+77% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$5,023,095
Period-end balance · 30 Sep 2024
|
|
| Accounts Receivable, after Allowance for Credit Loss, Current |
$187,682
Period-end balance · 30 Sep 2024
|
-38% |
| Additional Paid in Capital |
$89,537,725
Period-end balance · 30 Sep 2024
|
+16% |
| Assets |
$5,253,902
Period-end balance · 30 Sep 2024
|
-6.1% |
| Assets, Current |
$3,256,608
Period-end balance · 30 Sep 2024
|
-41% |
| Cash and Cash Equivalents, at Carrying Value |
$928,010
Period-end balance · 30 Sep 2024
|
-48% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2024
|
0% |
| Common Stock, Shares Authorized |
250,000,000
Period-end balance · 30 Sep 2024
|
+400% |
| Common Stock, Shares, Issued |
28,768,055
Period-end balance · 30 Sep 2024
|
+49% |
| Costs and Expenses |
$25,501,947
Trailing 12 months · 30 Sep 2024
|
+27% |
| Earnings Per Share, Basic |
-1
Trailing 12 months · 30 Sep 2024
|
-102% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
-$24,799,670
Trailing 12 months · 30 Sep 2024
|
-28% |
| Income Tax Expense (Benefit) |
$0
Trailing 12 months · 30 Sep 2024
|
|
| Inventory, Net |
$236,110
Period-end balance · 30 Sep 2024
|
+13% |
| Liabilities and Equity |
$5,253,902
Period-end balance · 30 Sep 2024
|
-6.1% |
| Liabilities, Current |
$18,720,099
Period-end balance · 30 Sep 2024
|
+183% |
| Nonoperating Income (Expense) |
-$110,951
Trailing 12 months · 30 Sep 2024
|
+32% |
| Operating Income (Loss) |
-$24,688,719
Trailing 12 months · 30 Sep 2024
|
-27% |
| Operating Lease, Liability, Current |
$20,116
Period-end balance · 30 Sep 2024
|
+12% |
| Operating Lease, Liability, Noncurrent |
$7,143
Period-end balance · 30 Sep 2024
|
-74% |
| Operating Lease, Right-of-Use Asset |
$26,636
Period-end balance · 30 Sep 2024
|
-41% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2024
|
0% |
| Preferred Stock, Shares Authorized |
5,000,000
Period-end balance · 30 Sep 2024
|
0% |
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 30 Sep 2024
|
|
| Property, Plant and Equipment, Net |
$19,988
Period-end balance · 30 Sep 2024
|
-51% |
| Research and Development Expense |
$15,974,463
Trailing 12 months · 30 Sep 2024
|
+21% |
| Retained Earnings (Accumulated Deficit) |
-$103,013,942
Period-end balance · 30 Sep 2024
|
-32% |
| Stockholders' Equity Attributable to Parent |
-$13,473,340
Period-end balance · 30 Sep 2024
|
-1180% |
Comparisons, sources and research notes
Sources and sharing
Cyclo Therapeutics, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2024
- Latest reported value
- Return On Equity 341%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2024
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2024.
- Most recent SEC facts end date on this page: 12 Nov 2024.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Cyclo Therapeutics, Inc.
Latest financial period: Q4 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
18 Dec 2024
Page type
Company facts
Latest period
Q3 2024
SEC-backed company facts were refreshed from filings filed on 18 Dec 2024.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 140% versus the comparable prior period.
Compared with
Compared with Cyclo Therapeutics, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2024.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- Cyclo Therapeutics, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2024.
- Headline metric: Return On Equity 341%.
Change
- Return On Equity YoY relative change: -140%.
- Most recent SEC facts end date: 12 Nov 2024.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2024-11-12) highlights Return On Equity 341.5%, Return On Assets -457.1%, and Current Ratio 0.17x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -22,517,553.0 USD · through 2024-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: 2,420.0 USD · through 2023-12-31 · reported annual SEC source
- Cash and equivalents: 928,010.0 USD · through 2024-09-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Ticker missing for issuer
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Cyclo Therapeutics, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: -28%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
32.1/100
Weak Confidence medium
Return On Equity
341%
Metric score 100.0/100
Return On Assets
-457%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.17x
- Quick Ratio
- 0.06x
Strengths
Return On Equity
Watchpoints
Return On Assets, Current Ratio, and Quick Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first